Sea Limited on Track for Longest Losing Streak Since May 2023 — Data Talk
Sea Limited Sponsored ADR Class A (SE) is currently at $64.31, down $0.90 or 1.38%
--Would be lowest close since May 2, 2024, when it closed at $63.98
--Currently down 11 consecutive days; down 13.92% over this period
--Longest losing streak since May 31, 2023, when it fell for 11 straight trading days
--Worst 11 day stretch since the 11 days ending Jan. 17, 2024, when it fell 14.02%
--Down 9.96% month-to-date; on pace for worst month since Nov. 2023, when it fell 13.14%
--Up 58.79% year-to-date
--Down 82.48% from its all-time closing high of $366.99 on Oct. 19, 2021
--Up 6.74% from 52 weeks ago (July 27, 2023), when it closed at $60.25
--Down 15.69% from its 52-week closing high of $76.28 on June 18, 2024
--Up 84.69% from its 52-week closing low of $34.82 on Jan. 17, 2024
--Traded as low as $63.30; lowest intraday level since May 14, 2024, when it hit $63.15
--Down 2.93% at today's intraday low; largest intraday percent decrease since July 17, 2024, when it fell as much as 3.87%
All data as of 11:19:11 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
July 25, 2024 11:37 ET (15:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks